Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects With Neovascular Age-related Macular Degeneration; NORSE EIGHT

Authors not listed

Outlook Therapeutics, Inc. · 2024

Abstract

Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-02 MST

Cite this

APA
Anonymous. (2024). Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects With Neovascular Age-related Macular Degeneration; NORSE EIGHT. <em>Outlook Therapeutics, Inc.</em>. https://clinicaltrials.gov/study/NCT06190093
Vancouver
Anonymous. Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects With Neovascular Age-related Macular Degeneration; NORSE EIGHT. Outlook Therapeutics, Inc.. 2024.
BibTeX
@misc{anon2024Safety, title = {Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects With Neovascular Age-related Macular Degeneration; NORSE EIGHT}, author = {Anonymous}, journal = {Outlook Therapeutics, Inc.}, year = {2024}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings